Indaptus Therapeutics Stock Forecast, Price & News

-1.24 (-12.30 %)
(As of 09/20/2021 03:37 PM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume16,196 shs
Average Volume7.42 million shs
Market Capitalization$47.79 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive INDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. The company is headquartered in Jerusalem, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.13 out of 5 stars

Medical Sector

1314th out of 1,352 stocks

Pharmaceutical Preparations Industry

643rd out of 665 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Indaptus Therapeutics (NASDAQ:INDP) Frequently Asked Questions

What stocks does MarketBeat like better than Indaptus Therapeutics?

Wall Street analysts have given Indaptus Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Indaptus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Indaptus Therapeutics' next earnings date?

Indaptus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Indaptus Therapeutics

Who are Indaptus Therapeutics' key executives?

Indaptus Therapeutics' management team includes the following people:
  • Jeffrey A. Meckler, Chief Executive Officer & Director
  • Nir Sassi, Chief Financial Officer
  • Michael James Newman, Director & Chief Scientific Officer
  • Walt A. Linscott, Chief Business Officer

Who are some of Indaptus Therapeutics' key competitors?

What is Indaptus Therapeutics' stock symbol?

Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP."

How do I buy shares of Indaptus Therapeutics?

Shares of INDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Indaptus Therapeutics' stock price today?

One share of INDP stock can currently be purchased for approximately $8.98.

How much money does Indaptus Therapeutics make?

Indaptus Therapeutics has a market capitalization of $48.55 million. The company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis.

How many employees does Indaptus Therapeutics have?

Indaptus Therapeutics employs 40 workers across the globe.

What is Indaptus Therapeutics' official website?

The official website for Indaptus Therapeutics is

Where are Indaptus Therapeutics' headquarters?

Indaptus Therapeutics is headquartered at 12 Hartom Street, Har Hotzvim, Jerusalem 777512.

How can I contact Indaptus Therapeutics?

Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The company can be reached via phone at (722) 586-4657 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.